Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial [Breast Cancer]

Conclusion Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.

http://jco.ascopubs.org/cgi/content/short/34/14/1601?rss=1

Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ribi, Luo, Bernhard, Francis, Burstein, Ciruelos, Bellet, Pavesi, Lluch, Visini, Parmar, Tondini, Kerbrat, Perello, Neven, Torres, Lombardi, Puglisi, Karlsson, Ruhstaller, Colleoni, Coates, Goldhirsch, Price, Gelber, Regan, Fleming Tags: Hormonal Therapy, Quality of Life, Menopausal Symptoms Breast Cancer Source Type: research